✔️ MITRAL VALVE Session ✔️ SOLACI-SOCIME 2022 Scientific Session 👨🏫 Content: 00:07 – Welcoming Words- Dr. Guering Eid Lidt (MEX) 01:26 – Mitral valve replacement – Dr. Ignacio Amat (ESP) 18:15 – Transcatheter treatment of mitral valve regurgitation – Dr. Luis Nombela Franco (ESP) 34:57 – Mitral valve-in-valve – Dr. Guering Eid Lidt (MEX)
Since its inception, transcatheter aortic valve replacement (TAVR) has improved greatly. However, there still are five big challenges to be solved: paravalvular leak, conduction disturbances, debilitating stroke, impaired kidney function, and major vascular complications and bleeding. Most cases of stroke are periprocedural and ischemic. So far, they have not been well analyzed in terms of...
TAVR has consolidated as an increasingly valid alternative to treat failed surgical aortic valve bioprostheses. One of the major challenges it presents is patients with small annuli treated with a surgical bioprosthesis. There is little data available about this scenario. A few observational studies have shown what appears to be a hemodynamic advantage of...
Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that decrease the restenosis rate. Recently, the IMPERIAL study showed greater patency at 1 year and greater freedom from clinically guided revascularization at 2 years in favor of the ELUVIA stent (paclitaxel-eluting fluoropolymer, FP-DES) compared with the ZILVER PTX...
We have reached the end of SOLACI Sessions 44th edition. We have enjoyed 2 days of intense scientific activities with multiple educational symposia, case study discussions, theoretical and practical approaches to issues of interest in interventional cardiology and fruitful knowledge exchange between prestigious colleagues from Paraguay and Latin America. With over 200 registered attendees and...
Same-day discharge (SDD) has been shown to be effective in angioplasties and some peripheral procedures, but the pandemic—because of the burden it caused on the healthcare system—has forced the optimization of hospitalization times for other pathologies and procedures. This strategy is yet to be tested in transcatheter aortic valve replacement (TAVR) due to the possible...
We invite the entire Latin American community to analyze challenging TAVR cases together with a panel of Latin American experts. We will be looking at vascular access sites, aortic anatomy, potential coronary compromise, Valve-in-Valve, and more! Date: March 24, 2022, at 07.30 PM (Argentinian/ Brazil time; UTC-3). The event will feature renowned experts from across...
The ISCHEMIA study keeps providing scientific news. This work in patients with stable coronary artery disease had already shown (to our surprise) that ischemic burden does not predict 4-year mortality. Now, this new analysis suggests that anatomic severity can predict events. However (surprisingly, once more), altering this severity through angioplasty does not change the prognosis...
Ideally, we will not puncture the femoral artery blindly if we are planning to use a big caliber releasing device and a percutaneous closure device during TAVR. The risk of a high or low puncture or the presence of a lateral branch compromising the puncture site might become a major vascular and bleeding complication. There...
Bifurcations have been, are and will be challenging. However, we have to admit we have gained experience and have more tools than pioneer interventionists and many of the early experts who have made history. This study assessed the ten-year trends in coronary bifurcation percutaneous coronary intervention (PCI) looking at patient and lesion characteristics, devices used,...